GlassScriptPhysician profile
Michaela Rose Abbott
NPI 1760031280
$8,018.20
in general payments reported to CMS, 2019-2025
31 companies · $3,589 in 2025
The $3,589 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $787 · 2023: $1,232 · 2024: $2,410 · 2025: $3,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,108 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,107.69 |
| Education | $123.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,166.08 | 2022-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $1,975.53 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $589.08 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $474.91 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $422.72 | 2023-2025 | Xolair |
| Csl Behring | $246.54 | 2023-2025 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $192.99 | 2023-2025 | Cuvitru, Eohilia, Takhzyro |
| Amgen INC. | $175.56 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $170.86 | 2025 | Neffy |
| Hospira, INC. | $139.26 | 2024-2025 | |
| Leo Pharma INC. | $130.68 | 2024-2025 | Adbry, Anzupgo |
| Regeneron Pharmaceuticals, INC. | $127.50 | 2024-2025 | Dupixent |
| Blueprint Medicines Corporation | $117.60 | 2022-2025 | Ayvakit |
| Pharming Healthcare, INC. | $110.61 | 2023-2025 | Ruconest |
| Aimmune Therapeutics, INC. | $108.29 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $99.52 | 2024-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $98.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $87.58 | 2024-2025 | |
| Lilly USA, LLC | $86.16 | 2025 | Ebglyss, Taltz |
| Optinose US, INC. | $80.93 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $78.44 | 2024-2025 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $70.75 | 2025 | Dawnzera |
| Abbvie INC. | $59.71 | 2024-2025 | |
| Organon LLC | $38.97 | 2025 | |
| Galderma Laboratories, L.P. | $36.82 | 2025 | Nemluvio |
| Kaleo, INC. | $31.09 | 2022-2023 | Auvi-Q |
| Dermavant Sciences, INC. | $28.91 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $20.65 | 2025 | Zoryve |
| Cycle Pharmaceuticals INC | $18.32 | 2025 | Sajazir |
| Seqirus USA INC | $17.10 | 2025 | Flucelvax |
| Octapharma USA, INC. | $16.05 | 2024 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.